Insights into implementation of sacubitril/valsartan into clinical practice.

ESC Heart Failure
Pieter MartensWilfried Mullens

Abstract

Sacubitril/valsartan significantly reduced heart failure hospitalization and mortality in PARADIGM-HF (Prospective Comparison of Angiotensin Receptor-Neprilysin Inhibitor With an Angiotensin-Converting Enzyme Inhibitor to Determine Impact on Global Mortality and Morbidity in Heart Failure). However, real-world data from its use are lacking. We retrospectively assessed all baseline and follow-up data of consecutive heart failure patients with reduced ejection fraction receiving therapy with sacubitril/valsartan for Class I recommendation between December 2016 and July 2017. Baseline characteristics and dose titration of sacubitril/valsartan were compared between patients in clinical practice and in PARADIGM-HF. A total of 120 patients (81% male) were switched from angiotensin-converting enzyme inhibitor or angiotensin receptor blocker to sacubitril/valsartan. A total of 20.1% of patients received dose uptitration. Patients were treated with an equipotential dose of renin-angiotensin system blockers before and after uptitration of sacubitril/valsartan (57 ± 29% vs. 53 ± 29% of target dose indicated by European Society of Cardiology guidelines; P = 0.286). However, they received a lower dose of sacubitril/valsartan in comparison w...Continue Reading

References

Aug 1, 1991·The New England Journal of Medicine·UNKNOWN SOLVD InvestigatorsJay N Cohn
Sep 2, 2014·The New England Journal of Medicine·John J V McMurrayUNKNOWN PARADIGM-HF Investigators and Committees
Nov 7, 2015·Journal of the American College of Cardiology·Joanne SimpsonUNKNOWN PARADIGM-HF Investigators and Committees
Dec 3, 2015·The New England Journal of Medicine·Brian ClaggettUNKNOWN PARADIGM-HF Investigators
Jun 11, 2016·European Journal of Heart Failure·Orly VardenyUNKNOWN Prospective Comparison of ARNI with ACEI to Determine Impact on Global Mortality and Morbidity in Heart Failure (PARADIGM-HF
Aug 30, 2016·Annals of Internal Medicine·Milton PackerMichael Emmett
Mar 1, 2017·European Journal of Heart Failure·Pierpaolo PellicoriAndrew L Clark
Oct 24, 2017·International Journal of Cardiology·Pieter MartensWilfried Mullens

❮ Previous
Next ❯

Citations

Dec 13, 2018·Journal of Cardiovascular Pharmacology·Amy X DuJustin A Ezekowitz
Apr 12, 2019·European Journal of Heart Failure·Rolf WachterKarel Kostev
Jun 1, 2018·American Journal of Cardiovascular Drugs : Drugs, Devices, and Other Interventions·Rex C Liu
Dec 29, 2019·European Journal of Heart Failure·Markus S AnkerStefan D Anker
Dec 31, 2019·ESC Heart Failure·Markus S AnkerWilhelm Haverkamp
Nov 9, 2019·ESC Heart Failure·Juan Carlos López-AzorManuel Martínez-Sellés
Jan 29, 2020·Journal of Cardiovascular Medicine·António Valentim GonçalvesRui C Ferreira
May 30, 2020·British Journal of Clinical Pharmacology·Cormac KennedyMichael Barry
Aug 3, 2020·Journal of Cardiovascular Medicine·Massimo MapelliPiergiuseppe Agostoni
Nov 8, 2019·Acta Cardiologica·Pieter MartensWilfried Mullens
Mar 2, 2019·Cardiovascular Drugs and Therapy·Carles Moliner-AbósEulàlia Roig
May 31, 2019·Internal and Emergency Medicine·Francesco SpannellaRiccardo Sarzani
May 31, 2019·International Journal of Molecular Sciences·Daniela Maria TanaseMariana Floria
Jun 21, 2019·Journal of Clinical Medicine·António Valentim GonçalvesRui Cruz Ferreira
Oct 30, 2020·ESC Heart Failure·Markus S AnkerStephan von Haehling
Oct 22, 2020·Arquivos brasileiros de cardiologia·António Valentim GonçalvesRui Cruz Ferreira
Dec 6, 2020·ESC Heart Failure·Daniela TomasoniMarco Metra
Feb 6, 2021·International Journal of Cardiology·Clare ProudfootMichele Senni
Oct 30, 2020·American Journal of Cardiovascular Drugs : Drugs, Devices, and Other Interventions·Sijing ChengWei Hua
Dec 11, 2020·Journal of Cardiovascular Pharmacology·Lindsey RerickBrooke Gengler
Mar 17, 2021·European Heart Journal. Quality of Care & Clinical Outcomes·Uwe ZeymerUNKNOWN ARIADNE investigators

❮ Previous
Next ❯

Software Mentioned

SPSS

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.